CN Patent
CN101842101A — 水杨酰苯胺修饰的肽用作口服治疗剂
Assigned to University of California San Diego UCSD · Expires 2010-09-22 · 16y expired
What this patent protects
本发明涉及令人惊讶的发现:水杨酰苯胺如氯硝柳胺和/或氯硝柳胺类似物可与治疗活性肽反应以产生修饰的肽络合物,其显示出增加的耐蛋白质水解性,和当口服给药时显示出比未修饰的肽高的生物活性。
USPTO Abstract
本发明涉及令人惊讶的发现:水杨酰苯胺如氯硝柳胺和/或氯硝柳胺类似物可与治疗活性肽反应以产生修饰的肽络合物,其显示出增加的耐蛋白质水解性,和当口服给药时显示出比未修饰的肽高的生物活性。
Drugs covered by this patent
- Ozempic (semaglutide) · Novo Nordisk
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.